NCT01266967 - A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2012

Conditions

Melanoma and Brain Metastases

Interventions

DRUG

GSK2118436

Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.

Trial Locations (24)

2145

GSK Investigational Site, Westmead

2300

GSK Investigational Site, Waratah

6009

GSK Investigational Site, Nedlands

10065

GSK Investigational Site, New York

10117

GSK Investigational Site, Berlin

13385

GSK Investigational Site, Marseille

15232

GSK Investigational Site, Pittsburgh

24105

GSK Investigational Site, Kiel

35128

GSK Investigational Site, Padua

37232

GSK Investigational Site, Nashville

45122

GSK Investigational Site, Essen

48019

GSK Investigational Site, Ann Arbor

59037

GSK Investigational Site, Lille

77030

GSK Investigational Site, Houston

80131

GSK Investigational Site, Napoli

90095

GSK Investigational Site, Los Angeles

92100

GSK Investigational Site, Boulogne-Billancourt

94115

GSK Investigational Site, San Francisco

94143

GSK Investigational Site, San Francisco

94805

GSK Investigational Site, Villejuif

98109

GSK Investigational Site, Seattle

T6G 1Z2

GSK Investigational Site, Edmonton

M5G 2M9

GSK Investigational Site, Toronto

H3T 1E2

GSK Investigational Site, Montreal